ADX-2191 for Retinitis Pigmentosa
This trial will test a new treatment for retinitis pigmentosa, a degenerative eye disease. Eight subjects will receive injections of the new drug in their worst seeing eye. Ocular structure and function will be evaluated.
- Retinitis Pigmentosa
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Are there any open enrolment slots in this experiment?
"Affirmative. According to clinicaltrials.gov, this medical investigation is actively searching for participants. It was first announced on July 14th 2022 and was most recently updated on September 26th 2022, with 8 recruits needed from a single location."
What potential side-effects should be expected from the consumption of ADX-2191?
"ADX-2191 has been evaluated to have a safety score of 2 since there are studies that attest to its harmlessness but lack evidence advocating for its effectiveness."
What is the current participation rate of this clinical experiment?
"Correct. Clinicaltrials.gov affirms that recruitment is still underway for this clinical trial, which was initially posted on July 14th 2022 and most recently revised on September 26th 2022. 8 patients need to be enrolled at one medical site."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
How responsive is this trial?
Typically responds via
Most responsive sites:
- Duke Eye Center: < 48 hours
Average response time
- < 2 Days